Clinical Trial Update: A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing hepatic arterial infusion with bevacizumab and sintilimab for unresectable hepatocellular carcinoma (BCLC A-stage).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Hepatic arterial infusion
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage | Phase 2 | Status: UNKNOWN